Trackinsight Releases 2025 Global ETF Survey: ETF Industry on Overdrive: Shifting Gears, Breaking New Barriers 13-05-2025, 08:00

Olon Continues its Growth Path and Announces a New Acquisition 4-09-2024, 16:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00